Phio next buyout candidate? 100% tumor clearance in phase 1 trading at a dollar. With Moderna in Phase 3, skyrocking 100%+
$PHIO$MRNA
AI SUMMARY — PHIO is trading at $1 with early-stage Phase 1 cancer immunotherapy showing complete tumor responses, positioned as a potential acquisition target following Moderna's Phase 3 success and massive valuation spike. Key risks include typical biotech hazards: Phase 1 data rarely translates to later stages, tiny sample sizes, high failure probability, and extreme speculative nature of pre-Phase 2 plays.
| TICKER | PHIO |
USER | u/saltpile13 |
| RATING |
BULLISH |
ENTRY |
$1.14
|
| POSITION |
4347 sh
SYN
|
BOOK VAL |
$4956.52 |
| CURRENT |
$1.15 |
P&L % |
+0.88%
|
| CURR VAL |
$5000.00 |
P&L $ |
+43.48
|
| TICKER | MRNA |
USER | u/saltpile13 |
| RATING |
BULLISH |
ENTRY |
$174.16
|
| POSITION |
28 sh
SYN
|
BOOK VAL |
$4993.84 |
| CURRENT |
$145.13 |
P&L % |
-16.67%
|
| CURR VAL |
$4161.31 |
P&L $ |
-832.53
|
Longtime lurker.
After watching $MRNA go absolutely nuclear on its Phase 3 cancer-vaccine data, I started looking farther down the oncology pipeline.
PHIO is sitting near $1 with a tiny valuation while developing an RNAi cancer immunotherapy.
The interesting part: early Phase 1 data from PH-762 has reported complete responses in treated tumors in some patients. Obviously Phase 1 ≠ Phase 3, tiny sample sizes matter, and this could still completely fail.
But that's exactly why the valuation is interesting.
Moderna just demonstrated how violently the market can reprice an oncology platform once clinical validation gets strong enough. PHIO is much earlier, much smaller and exponentially more speculative.
Idk. I want to be early. Idk how y'all catch stocks early that turn into 100% within nanoseconds.